New brush test detects oral cancer in one hour
· Medical Xpressby Queen Mary, University of London
edited by Gaby Clark, reviewed by Andrew Zinin
Gaby Clark
Scientific Editor
Meet our editorial team
Behind our editorial process
Andrew Zinin
Chief Editor
Meet our editorial team
Behind our editorial process Editors' notes
This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
fact-checked
trusted source
proofread
The GIST Add as preferred source
A paper published in the journal Biomarker Research by a cross-university team led by Queen Mary University of London researchers validates the use of a noninvasive brush biopsy test that can detect oral cancer within one hour.
This test could revolutionize oral cancer detection and prevent more than 90% of unnecessary harmful scalpel biopsy procedures. These can be very painful, lead to infection and, in some areas of the mouth, such as the gum, are hard to carry out and may damage the underlying tooth and bone structure.
Oral cancer is a growing global killer. According to Global Burden of Disease data, lip and oral cancer are among the world's most rapidly increasing causes of early death. More than 10,000 people in the UK were diagnosed with oral cancer last year, according to the charity Mouth Cancer, and 3,637 people died. Worldwide, it affects 650,000 people a year. Risk factors include tobacco use and smoking, alcohol, infection with the HPV virus, and sun damage. Unfortunately, more than half (53%) of all mouth cancers are diagnosed in stage IV, when the cancer is at its most advanced.
The study is the largest of its kind, involving more than 1,000 samples from 545 patients.
Early diagnosis: The problem with scalpel biopsies
Early diagnosis of oral cancer (oral squamous cell carcinoma OSCC) is critical, yet most oral potentially malignant disorders (OPMDs) are benign, and patients frequently undergo unnecessary invasive scalpel biopsies, creating diagnostic delays and patient harm. A scalpel oral biopsy can be extremely painful—especially on the tongue (the most common cancer site)—because part of the tongue is cut off. This discourages both patients and clinicians from doing this repeatedly and in a timely way.
A noninvasive tool is urgently needed for long-term surveillance and timely OSCC detection.
This study aimed to find out whether a successful microbiopsy-based multigene assay (qMIDS-V2) could be adapted into a rapid, noninvasive brush biopsy test (qMIDS-V3) for accurate OSCC detection. It found that this new test works, potentially sparing more than 90% of low-risk OPMD patients from unnecessary invasive tissue biopsies.
The lead researcher, Muy-Teck Teh, professor of molecular oral oncology at Queen Mary, said, "Oral cancer survival is directly linked to how early it is found, yet our current diagnostic pathway is blunt—most patients with a suspicious lesion end up having an invasive biopsy even when the overwhelming likelihood is that it is benign. This test changes that. It gives clinicians a rapid, accurate and noninvasive way to triage patients, and crucially, it can be repeated. That means we can now monitor patients with persistent pre-malignant lesions regularly and systematically—and pick up cancers much earlier than we would have been able to before."
In the UK, a 10-year audit reported a 450% rise in two-week-wait referrals alongside a 50% drop in the cancer detection rate. Subsequent audits showed that 92.5%–99.5% of referred patients were cancer-free, with most (96%–98%) remaining cancer-free at five-year follow-up. These findings highlight substantial overreferral and inefficiency in current pathways.
Implementing a rapid, noninvasive triage test such as qMIDS-V3 could reduce unnecessary referrals for more than 90% of cancer-free patients and lessen the clinical and financial burden of managing OPMDs and OSCC. Furthermore, qMIDS-V3 supports repeat brush biopsy, a critical capability for long-term surveillance, facilitating the detection of malignant transformation in OPMD patients while avoiding the need for multiple scalpel biopsies.
Is there anything surprising about the results?
This latest study builds on a substantial body of prior clinical validation. The second-generation test, qMIDS-V2, was developed as a microbiopsy-based assay—a minimally invasive technique requiring only 1 millimeter of tissue sample—and validated across more than 530 samples from three countries: the UK, India and China. That cross-continental validation established the robustness of the underlying multigene signature across diverse patient populations and clinical settings.
What makes the findings of this new study so striking is that qMIDS-V3—which requires only a noninvasive brush swab of the mouth, with no tissue removal whatsoever—achieves test performance that is highly comparable to its microbiopsy predecessor.
Teh added, "We were genuinely astonished by the fact that the brush swab test performance is comparable to a microbiopsy. It suggests that the biological signal captured by these four genes is sufficiently strong and consistent that it can be detected even from the superficial exfoliated cells collected by a brush biopsy. The clinical implications are significant: Patients no longer need even a minimally invasive procedure to benefit from molecularly guided triage."
A new tool for monitoring high-risk patients
Beyond initial diagnosis, the test offers a further clinical benefit that has not previously been available at scale: Because it is noninvasive and repeatable, it can be used to monitor patients with persistent OPMDs over time—conditions known to carry a risk of malignant transformation that is difficult to predict clinically. Serial testing could significantly improve the chances of detecting early-stage cancers in this high-risk group, at a point when treatment is most likely to be successful and survival outcomes are best.
The team included researchers from Queen Mary University of London's Centre for Oral Immunobiology & Regenerative Medicine, King George's Medical University in India, Modern Dental College & Research Centre in India, and the All India Institute of Medical Sciences.
More information
Muy-Teck Teh et al, INHBA–S100A16 dysregulation enables a non-invasive molecular stratification platform for rapid detection of oral squamous cell carcinoma: results from a large diagnostic case-control study, Biomarker Research (2026). DOI: 10.1186/s40364-026-00963-7
Key medical concepts
Clinical categories
DentistryOncologyLaboratory medicine Provided by Queen Mary, University of London Who's behind this story?
Gaby Clark
MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →
Andrew Zinin
Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →
Citation: New brush test detects oral cancer in one hour (2026, July 6) retrieved 7 July 2026 from https://medicalxpress.com/news/2026-07-oral-cancer-hour.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.